Korea IPO round-up: Samsung Bioepis plans Nasdaq float as Jeju Air files
Samsung Bioepis, the pharmaceutical arm of Korea’s Samsung Group, is planning a highly-anticipated IPO on the Nasdaq in 2016, and has dished out mandates for the listing to four banks.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts